Crossing a Barrier in the Study of Neurological Disease
News Mar 02, 2016
The blood-brain barrier at the interface between the brain’s blood vessels and nerve cells acts as a vital gatekeeper to the brain, allowing essential nutrients and fluids to pass into the central nervous system and the web of our brain’s neurons while keeping out harmful toxins and bacterial infection. Yet this barrier is so effective that it can also block the delivery of therapies for treating neurological diseases or brain injury.
A team at the Wyss Institute for Biologically Inspired Engineering, led by Wyss Institute Founding Director Donald Ingber, M.D., Ph.D., has advanced the Institute’s Human Organs-on-Chips technology by developing a method for modeling the 3D structure of the human blood-brain barrier inside a microfluidic device, which will help scientists study human neurovascular function and inflammation in vitro.
"The blood-brain barrier is the first line of defense against chemicals and molecules that could induce brain injury, but it also blocks transport of potentially life-saving therapeutics to the central nervous system," said Ingber, who is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and the Vascular Biology Program at Boston Children’s Hospital, as well as Professor of Bioengineering at the Harvard John A. Paulson School of Engineering and Applied Sciences.
"It’s very difficult to get small molecule drugs and biologics into the brain due to the blood-brain barrier, and until now there hasn’t been a good in vitro model for studying the multi-cellular interactions that govern the barrier’s permeability in humans," said Anna Herland, Ph.D., a postdoctoral fellow at the Wyss Institute and the first author on the new study.
To develop their 3D blood-brain barrier on-a-chip, the team used a microengineering technique to fabricate a hollow blood vessel lined by human endothelial cells surrounded by an extracellular matrix containing human pericytes and astrocytes that together form the blood-brain barrier within the microvessels of our own brains.
They did so by forming a microchannel inside a clear, polymer chip, filling the channel with collagen matrix containing human brain astrocyte cells, and then forming a long narrow lumen from one end to the other using a "viscous fingering" method. The resulting lumen, representing the shape of a blood vessel, was then seeded with human brain pericyte cells and, finally, lined with living human endothelial cells that normally build the interior surfaces of our vessel walls.
Strikingly, over the course of the study, the human cells self-assembled to take on their normal positions as seen in vivo, with the pericytes in close apposition to the endothelial cells and the astrocytes cells extending through the collagen matrix to contact the endothelial cells. The cells, nourished by nutrients and a blood substitute flowing through the vessel-like microchannel, reconstituted a blood-brain barrier to small molecules similar to that seen in vivo.
Using this model, the Wyss team studied neuroinflammatory responsein vitro by introducing a pro-inflammatory protein that is associated with several diseases of the central nervous system including Alzheimer’s, stroke, brain ischemia, multiple sclerosis, traumatic brain injury, and others. The experiment revealed that both pericyte and astrocyte cells can modulate the production of neuroprotective proteins, and that these cells can also act independently of one another in their response to inflammation signals.
The newfound ability to study these complex interactions in vitro is a significant advance when compared to traditional cell culture techniques, which do not mimic the physiologically relevant 3D orientation of different cell types and structures like the blood-brain barrier on-a-chip. This new device can be used to investigate the cause and effects of neuroinflammation, which play a central role in many neurological disorders, as well as to identify potential new approaches to develop drugs that selectively cross the human blood-brain barrier.
Integrated Lead Discovery: An Evolving ToolboxNews
A new SLAS Discovery review article offers an informative guide to the established and emerging tools available for early drug discovery and screening, and provides illustrative scenarios demonstrating considerations that drive decisions on choice of lead discovery tactics.READ MORE
New Ovarian Cancer TargetNews
Researchers have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer. This new study opens a potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer.READ MORE
Comments | 0 ADD COMMENT
27th International Conference on Nanomedicine and Nanomaterials
Oct 18 - Oct 19, 2018